<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648919</url>
  </required_header>
  <id_info>
    <org_study_id>HUANG-2015-1</org_study_id>
    <nct_id>NCT02648919</nct_id>
  </id_info>
  <brief_title>Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer</brief_title>
  <official_title>Phase II Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Hawaii Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of Noni extract in men diagnosed with
      very low risk or low risk prostate cancer
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Genomic Prostate Score in prostatic tumors</measure>
    <time_frame>Change from screening and at 12 months or early termination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of disease progression of prostate cancer</measure>
    <time_frame>Change from screening and at 12 months or early termination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of Noni extract on serum PSA in men diagnosed with very low risk or low risk prostate cancer</measure>
    <time_frame>3,6,9, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of Noni extract in men diagnosed with very low risk or low risk prostate cancer as assessed by CTCAE v4.0</measure>
    <time_frame>Enrollment, 1, 3, 6, 9, and 12 months, and 7 days post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the molecular pathways contributing to the activities associated with Noni extract in the prostate cancer (e.g., angiogenesis, cell proliferation, and apoptosis in prostate tissue biopsy samples) via immunohistochemistry (IHC) staining.</measure>
    <time_frame>Enrollment, 6, 9 and 12 months or at early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of Noni extract on lower urinary tract symptoms via the American Urological Association (AUA) Benign Prostatic Hyperplasia (BPH) Symptom Score Index</measure>
    <time_frame>Enrollment, 3, 6, 9 and 12 months or at early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of Noni extract on quality of life via QoL questionnaire</measure>
    <time_frame>Enrollment, 3, 6, 9 and 12 months or at early termination</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Noni 6,000 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Noni extract 6,000 mg/day (4 capsules, 3 times per day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Noni extract</intervention_name>
    <description>Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.</description>
    <arm_group_label>Noni 6,000 mg/day</arm_group_label>
    <other_name>Healing Noni</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men with a diagnosis of very low risk (&lt;5% risk of disease relapse after primary
             treatment, criteria; cT1c, Gleason &lt;6, PSA &lt; 10 ng/mL, fewer than 3 positive biopsy
             cores &lt; 50% cancer in any core, PSA density &lt; 0.15 ng/mL/g); low risk (10% risk of
             disease relapse after primary treatment, criteria; cT1-2a, Gleason &lt;6, PSA &lt; 10 ng/mL)
             prostate cancer

          2. Very low risk and low risk groups will be confirmed by Oncotype DX prostate cancer
             test and provided a Genomic Prostate Score (GPS)

          3. 60 years of age and older (&gt; 60 years) at the time of informed consent

          4. No evidence of extraprostatic disease on 3T multiparametric pelvic MRI

          5. No baseline PT/PTT abnormalities, coagulopathies, or who are on any blood thinners.

          6. ECOG performance status 0âˆ’2

          7. Participants must have normal organ and marrow function as demonstrated by the
             following parameters being:

               -  complete blood count (CBC) - no clinically significant findings

               -  complete metabolic profile (CMP) - no clinically significant findings

               -  lactate dehydrogenase (LDH) - no clinically significant findings

          8. Willing to comply with proposed visit and treatment schedule

          9. Able to understand and willing to sign a written informed consent document

        Exclusion Criteria:

          1. Prior history of treated prostate cancer

          2. Concomitant use of medications that are known CYP3A4 substrates

          3. Use of medications or supplements that are known to affect PSA within 30 days prior to
             informed consent, including toremifene citrate, finasteride, testosterone,
             dehydroepiandrosterone (DHEA) or other testosterone-like supplements. No dutasteride
             within 90 days prior to informed consent

          4. Consumption of any concomitant nutritional, herbal supplements, and antioxidants
             should be taken under the discretion of the investigator. The following
             foods/supplements are prohibited at least 7 days prior to initiation of and during
             study treatment:

               -  St. John's wort or hyperforin (potent CYP3A4 enzyme inducer)

               -  Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor)

          5. Consumption or use of any Noni or Noni-containing products

          6. History of renal or hepatic disease, including history of hepatitis B or C

          7. Participation in any other investigational study or use of any other investigational
             agents within 30 days prior to study entry

          8. History of allergic reactions attributed to Noni or other compounds of similar
             chemical or biologic composition to Noni, or the inactive components present in Noni
             capsules. Uncontrolled intercurrent illness including, but not limited to, ongoing or
             active infection, symptomatic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia, or any psychological, familial, sociological or other concomitant
             condition that would not allow adequate compliance with the study protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Huang, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Huang, PharmD</last_name>
    <phone>808-564-5994</phone>
    <email>JeffHuang@cc.hawaii.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles J Rosser, MD, MBA</last_name>
    <phone>808-564-5994</phone>
    <email>CRosser@cc.hawaii.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Huang, PharmD</last_name>
      <phone>808-564-5994</phone>
      <email>JeffHuang@cc.hawaii.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mendy Dunn, BSN</last_name>
      <phone>808-564-5994</phone>
      <email>MDunn@cc.hawaii.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Huang, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles J Rosser, MD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Issell, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sergei Tikhonenkov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Issell BF, Franke A, Fielding RM. Pharmacokinetic study of Noni fruit extract. J Diet Suppl. 2008;5(4):373-82. doi: 10.1080/19390210802519671.</citation>
    <PMID>22436097</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2015</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Hawaii</investigator_affiliation>
    <investigator_full_name>Charles Rosser</investigator_full_name>
    <investigator_title>Director of Clinical and Translational Research Program</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

